Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.

PMID:
30021885
2.

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.

Tang J, Tanoli ZU, Ravikumar B, Alam Z, Rebane A, Vähä-Koskela M, Peddinti G, van Adrichem AJ, Wakkinen J, Jaiswal A, Karjalainen E, Gautam P, He L, Parri E, Khan S, Gupta A, Ali M, Yetukuri L, Gustavsson AL, Seashore-Ludlow B, Hersey A, Leach AR, Overington JP, Repasky G, Wennerberg K, Aittokallio T.

Cell Chem Biol. 2018 Feb 15;25(2):224-229.e2. doi: 10.1016/j.chembiol.2017.11.009. Epub 2017 Dec 21.

3.

Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men.

Suvitaival T, Bondia-Pons I, Yetukuri L, Pöhö P, Nolan JJ, Hyötyläinen T, Kuusisto J, Orešič M.

Metabolism. 2018 Jan;78:1-12. doi: 10.1016/j.metabol.2017.08.014. Epub 2017 Sep 20.

4.

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner.

Posada IMD, Lectez B, Sharma M, Oetken-Lindholm C, Yetukuri L, Zhou Y, Aittokallio T, Abankwa D.

Oncotarget. 2017 Jul 4;8(27):44550-44566. doi: 10.18632/oncotarget.17819.

5.

Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.

Söderholm S, Fu Y, Gaelings L, Belanov S, Yetukuri L, Berlinkov M, Cheltsov AV, Anders S, Aittokallio T, Nyman TA, Matikainen S, Kainov DE.

Viruses. 2016 Sep 29;8(10). pii: E269. Review.

6.

Genomic prediction of coronary heart disease.

Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, Tikkanen E, Perola M, Schunkert H, Sijbrands EJ, Palotie A, Samani NJ, Salomaa V, Ripatti S, Inouye M.

Eur Heart J. 2016 Nov 14;37(43):3267-3278. Epub 2016 Sep 21.

7.

Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol.

Laurila PP, Surakka I, Sarin AP, Yetukuri L, Hyötyläinen T, Söderlund S, Naukkarinen J, Tang J, Kettunen J, Mirel DB, Soronen J, Lehtimäki T, Ruokonen A, Ehnholm C, Eriksson JG, Salomaa V, Jula A, Raitakari OT, Järvelin MR, Palotie A, Peltonen L, Oresic M, Jauhiainen M, Taskinen MR, Ripatti S.

Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):847-57. doi: 10.1161/ATVBAHA.112.300733. Epub 2013 Feb 14.

PMID:
23413431
8.

T-cell activation induces selective changes of cellular lipidome.

Lonnberg T, Yetukuri L, Seppanen-Laakso T, Lahesmaa R, Oresic M.

Front Biosci (Elite Ed). 2013 Jan 1;5:558-73.

PMID:
23277012
9.

Metabolic regulation in progression to autoimmune diabetes.

Sysi-Aho M, Ermolov A, Gopalacharyulu PV, Tripathi A, Seppänen-Laakso T, Maukonen J, Mattila I, Ruohonen ST, Vähätalo L, Yetukuri L, Härkönen T, Lindfors E, Nikkilä J, Ilonen J, Simell O, Saarela M, Knip M, Kaski S, Savontaus E, Orešič M.

PLoS Comput Biol. 2011 Oct;7(10):e1002257. doi: 10.1371/journal.pcbi.1002257. Epub 2011 Oct 27.

10.

High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy.

Yetukuri L, Huopaniemi I, Koivuniemi A, Maranghi M, Hiukka A, Nygren H, Kaski S, Taskinen MR, Vattulainen I, Jauhiainen M, Orešič M.

PLoS One. 2011;6(8):e23589. doi: 10.1371/journal.pone.0023589. Epub 2011 Aug 24.

11.

Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans.

Pietiläinen KH, Róg T, Seppänen-Laakso T, Virtue S, Gopalacharyulu P, Tang J, Rodriguez-Cuenca S, Maciejewski A, Naukkarinen J, Ruskeepää AL, Niemelä PS, Yetukuri L, Tan CY, Velagapudi V, Castillo S, Nygren H, Hyötyläinen T, Rissanen A, Kaprio J, Yki-Järvinen H, Vattulainen I, Vidal-Puig A, Orešič M.

PLoS Biol. 2011 Jun;9(6):e1000623. doi: 10.1371/journal.pbio.1000623. Epub 2011 Jun 7.

12.

Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.

Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyötyläinen T, Kallioniemi O, Iljin K, Oresic M.

Cancer Res. 2011 May 1;71(9):3236-45. doi: 10.1158/0008-5472.CAN-10-3894. Epub 2011 Mar 17.

13.

Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol.

Yetukuri L, Söderlund S, Koivuniemi A, Seppänen-Laakso T, Niemelä PS, Hyvönen M, Taskinen MR, Vattulainen I, Jauhiainen M, Oresic M.

J Lipid Res. 2010 Aug;51(8):2341-51. doi: 10.1194/jlr.M006494. Epub 2010 Apr 29.

14.

The gut microbiota modulates host energy and lipid metabolism in mice.

Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, Felin J, Perkins R, Borén J, Oresic M, Bäckhed F.

J Lipid Res. 2010 May;51(5):1101-12. doi: 10.1194/jlr.M002774. Epub 2009 Dec 29.

15.

Adaptation and failure of pancreatic beta cells in murine models with different degrees of metabolic syndrome.

Medina-Gomez G, Yetukuri L, Velagapudi V, Campbell M, Blount M, Jimenez-Linan M, Ros M, Oresic M, Vidal-Puig A.

Dis Model Mech. 2009 Nov-Dec;2(11-12):582-92. doi: 10.1242/dmm.003251. Epub 2009 Oct 19.

16.

Bioinformatics strategies for the analysis of lipids.

Wheelock CE, Goto S, Yetukuri L, D'Alexandri FL, Klukas C, Schreiber F, Oresic M.

Methods Mol Biol. 2009;580:339-68. doi: 10.1007/978-1-60761-325-1_19.

PMID:
19784609
17.

Gut microbiota affects lens and retinal lipid composition.

Oresic M, Seppänen-Laakso T, Yetukuri L, Bäckhed F, Hänninen V.

Exp Eye Res. 2009 Nov;89(5):604-7. doi: 10.1016/j.exer.2009.06.018. Epub 2009 Jul 8.

PMID:
19591827
18.

Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome.

Lankinen M, Schwab U, Gopalacharyulu PV, Seppänen-Laakso T, Yetukuri L, Sysi-Aho M, Kallio P, Suortti T, Laaksonen DE, Gylling H, Poutanen K, Kolehmainen M, Oresic M.

Nutr Metab Cardiovasc Dis. 2010 May;20(4):249-57. doi: 10.1016/j.numecd.2009.04.009. Epub 2009 Jun 23.

PMID:
19553094
19.

Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations.

Kotronen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen J, Taskinen MR, Oresic M, Yki-Järvinen H.

Diabetologia. 2009 Apr;52(4):684-90. doi: 10.1007/s00125-009-1282-2. Epub 2009 Feb 13.

PMID:
19214471
20.

Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes.

Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O.

J Exp Med. 2008 Dec 22;205(13):2975-84. doi: 10.1084/jem.20081800. Epub 2008 Dec 15.

21.

Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism--the GENOBIN study.

Schwab U, Seppänen-Laakso T, Yetukuri L, Agren J, Kolehmainen M, Laaksonen DE, Ruskeepää AL, Gylling H, Uusitupa M, Oresic M; GENOBIN Study Group.

PLoS One. 2008 Jul 9;3(7):e2630. doi: 10.1371/journal.pone.0002630.

22.

Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice.

Minehira K, Young SG, Villanueva CJ, Yetukuri L, Oresic M, Hellerstein MK, Farese RV Jr, Horton JD, Preitner F, Thorens B, Tappy L.

J Lipid Res. 2008 Sep;49(9):2038-44. doi: 10.1194/jlr.M800248-JLR200. Epub 2008 Jun 1.

23.

Informatics and computational strategies for the study of lipids.

Yetukuri L, Ekroos K, Vidal-Puig A, Oresic M.

Mol Biosyst. 2008 Feb;4(2):121-7. doi: 10.1039/b715468b. Epub 2007 Dec 18. Review.

PMID:
18213405
24.

Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles.

Sysi-Aho M, Vehtari A, Velagapudi VR, Westerbacka J, Yetukuri L, Bergholm R, Taskinen MR, Yki-Järvinen H, Oresic M.

Bioinformatics. 2007 Jul 1;23(13):i519-28.

PMID:
17646339
25.

Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity.

Kolak M, Westerbacka J, Velagapudi VR, Wågsäter D, Yetukuri L, Makkonen J, Rissanen A, Häkkinen AM, Lindell M, Bergholm R, Hamsten A, Eriksson P, Fisher RM, Oresic M, Yki-Järvinen H.

Diabetes. 2007 Aug;56(8):1960-8. Epub 2007 Jul 9.

26.

PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism.

Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppänen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A.

PLoS Genet. 2007 Apr 27;3(4):e64.

27.

Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis.

Yetukuri L, Katajamaa M, Medina-Gomez G, Seppänen-Laakso T, Vidal-Puig A, Oresic M.

BMC Syst Biol. 2007 Feb 15;1:12.

28.

Normalization method for metabolomics data using optimal selection of multiple internal standards.

Sysi-Aho M, Katajamaa M, Yetukuri L, Oresic M.

BMC Bioinformatics. 2007 Mar 15;8:93.

29.

Data integration and visualization system for enabling conceptual biology.

Gopalacharyulu PV, Lindfors E, Bounsaythip C, Kivioja T, Yetukuri L, Hollmén J, Oresic M.

Bioinformatics. 2005 Jun;21 Suppl 1:i177-85.

PMID:
15961455

Supplemental Content

Loading ...
Support Center